Cargando…
Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice
OBJECTIVE: We investigated the impact of tyrosine kinase inhibitor (imatinib or dasatinib) coadministration with cyclophosphamide (Cp) on preantral follicle development in an in vitro mouse model. METHODS: Seventy-three female BDF1 mice were allocated into four experimental groups: group A, saline;...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Reproductive Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711100/ https://www.ncbi.nlm.nih.gov/pubmed/33227183 http://dx.doi.org/10.5653/cerm.2020.03755 |
_version_ | 1783618073674121216 |
---|---|
author | Hong, Yeon Hee Kim, Se Jeong Kim, Seul Ki Lee, Seung-Chan Jun, Jin Hyun Jee, Byung Chul Kim, Seok Hyun |
author_facet | Hong, Yeon Hee Kim, Se Jeong Kim, Seul Ki Lee, Seung-Chan Jun, Jin Hyun Jee, Byung Chul Kim, Seok Hyun |
author_sort | Hong, Yeon Hee |
collection | PubMed |
description | OBJECTIVE: We investigated the impact of tyrosine kinase inhibitor (imatinib or dasatinib) coadministration with cyclophosphamide (Cp) on preantral follicle development in an in vitro mouse model. METHODS: Seventy-three female BDF1 mice were allocated into four experimental groups: group A, saline; group B, Cp (25 mg/kg); group C, Cp (25 mg/kg) and imatinib (7.5 mg/kg); and group D, Cp (25 mg/kg) and dasatinib (7.5 mg/kg). Preantral follicles were isolated and cultured in vitro up to 12 days. Final oocyte acquisition and spindle integrity of metaphase II (MII) oocytes were assessed. Levels of 17β-estradiol and anti-Müllerian hormone (AMH) in the final spent media were measured by enzyme-linked immunosorbent assays, and the mRNA levels of Star, Sod1, Mapk3, and Casp3 in the final follicular cells were quantified by real-time polymerase chain reaction. RESULTS: The percentage of MII oocytes per initiated follicle, the proportion of MII oocytes with normal spindles, and the 17β-estradiol level were similar in all four groups. The median AMH level in group B (7.74 ng/mL) was significantly lower than that in group A (10.84 ng/mL). However, the median AMH levels in group C (9.96 ng/mL) and group D (9.71 ng/mL) were similar to that in group A. The mRNA expression levels of Star, Sod1, Mapk3, and Casp3 were similar in all four groups. CONCLUSION: Coadministration of imatinib or dasatinib with Cp could preserve AMH production capacity in this in vitro mice preantral follicle culture model, and it did not affect MII oocyte acquisition. |
format | Online Article Text |
id | pubmed-7711100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Society for Reproductive Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-77111002020-12-09 Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice Hong, Yeon Hee Kim, Se Jeong Kim, Seul Ki Lee, Seung-Chan Jun, Jin Hyun Jee, Byung Chul Kim, Seok Hyun Clin Exp Reprod Med Original Article OBJECTIVE: We investigated the impact of tyrosine kinase inhibitor (imatinib or dasatinib) coadministration with cyclophosphamide (Cp) on preantral follicle development in an in vitro mouse model. METHODS: Seventy-three female BDF1 mice were allocated into four experimental groups: group A, saline; group B, Cp (25 mg/kg); group C, Cp (25 mg/kg) and imatinib (7.5 mg/kg); and group D, Cp (25 mg/kg) and dasatinib (7.5 mg/kg). Preantral follicles were isolated and cultured in vitro up to 12 days. Final oocyte acquisition and spindle integrity of metaphase II (MII) oocytes were assessed. Levels of 17β-estradiol and anti-Müllerian hormone (AMH) in the final spent media were measured by enzyme-linked immunosorbent assays, and the mRNA levels of Star, Sod1, Mapk3, and Casp3 in the final follicular cells were quantified by real-time polymerase chain reaction. RESULTS: The percentage of MII oocytes per initiated follicle, the proportion of MII oocytes with normal spindles, and the 17β-estradiol level were similar in all four groups. The median AMH level in group B (7.74 ng/mL) was significantly lower than that in group A (10.84 ng/mL). However, the median AMH levels in group C (9.96 ng/mL) and group D (9.71 ng/mL) were similar to that in group A. The mRNA expression levels of Star, Sod1, Mapk3, and Casp3 were similar in all four groups. CONCLUSION: Coadministration of imatinib or dasatinib with Cp could preserve AMH production capacity in this in vitro mice preantral follicle culture model, and it did not affect MII oocyte acquisition. Korean Society for Reproductive Medicine 2020-12 2020-11-24 /pmc/articles/PMC7711100/ /pubmed/33227183 http://dx.doi.org/10.5653/cerm.2020.03755 Text en Copyright © 2020. THE KOREAN SOCIETY FOR REPRODUCTIVE MEDICINE This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hong, Yeon Hee Kim, Se Jeong Kim, Seul Ki Lee, Seung-Chan Jun, Jin Hyun Jee, Byung Chul Kim, Seok Hyun Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title | Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title_full | Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title_fullStr | Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title_full_unstemmed | Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title_short | Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
title_sort | impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711100/ https://www.ncbi.nlm.nih.gov/pubmed/33227183 http://dx.doi.org/10.5653/cerm.2020.03755 |
work_keys_str_mv | AT hongyeonhee impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT kimsejeong impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT kimseulki impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT leeseungchan impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT junjinhyun impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT jeebyungchul impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice AT kimseokhyun impactofimatinibordasatinibcoadministrationoninvitropreantralfollicledevelopmentandoocyteacquisitionincyclophosphamidetreatedmice |